IDEXX LABORATORIES INC /DE (IDXX)
In Vitro & In Vivo Diagnostic Substances · In Vitro & In Vivo Diagnostic Substances · NASDAQ
$562.20
+1.60%
Investingg Score
65.5 / 100
Hold
Business overview
- Gross margin of 61.8%
- Operating margin of 31.6%
- Free cash flow margin of 24.6%
These high margins demonstrate robust operational efficiency and strong pricing power within its diagnostic products business.
Financial health
- Solid balance sheet risk score of 100
- FCF yield of 2.4%
- Operating margin of 31.6%
These metrics indicate a stable financial foundation with consistent cash generation capabilities.
- Gross Margin
- 61.8%
- Operating Margin
- 31.6%
- Current Ratio
- 1.2x
- Debt / Equity
- 0.23
- Free Cash Flow (TTM)
- $1.1B
- Interest Coverage
- 35x
Valuation
- Price-to-earnings ratio of 37.8
- Forward P/E ratio of 35.55
- Price-to-sales ratio of 9.8
These elevated multiples indicate that the market has priced in significant future expectations, creating potential valuation risk.
- P/E (TTM)
- 37.8x
- Forward P/E
- 35.5x
- Price / Sales
- 9.8x
- EV / EBITDA
- 27.1x
- FCF Yield
- 2.4%
Key risks
- High valuation multiples such as a 37.8 P/E ratio introduce downside risk if growth expectations are not met.
- Technical indicators show a sideways trend with the price 8.8 percent below the 200-day SMA, signaling lingering downward pressure.
- Uncertainty regarding sustained double-digit revenue growth in future periods.
Market cap $44.8B · data as of 2026-08-19
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze IDXX with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.